Want to see NZ:BLT full AI Analyst Report?
BLIS Technologies Limited (BLT) Stock Price & Analysis
BLT Stock Chart & Stats
- Day’s Range
- NZD 0.02 - NZD 0.02
- 52-Week Range
- NZD 0.01 - NZD 0.03
- Previous Close
- NZD 0.02
- Volume
- N/A
- Average Volume (3M)
- 322.56K
- Market Cap
- NZD 29.42M
- Enterprise Value
- NZD 16.90T
- Total Cash (Recent Filing)
- NZD 8.51M
- Total Debt (Recent Filing)
- NZD 439.00K
- Price to Earnings (P/E)
- 50.0
- Beta
- 0.29
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue Growth
The sustained increase in revenue indicates stronger commercial traction for BLIS’s probiotic products and partner-ingredient model. Continued top-line expansion can improve operating leverage, support broader market penetration, and provide a durable foundation for rebuilding profitability over the next several quarters.
Conservative Leverage
Very low leverage limits refinancing exposure and preserves financial flexibility for product development, commercial investment, and working-capital needs. Growing equity alongside assets also strengthens the balance sheet, giving the company greater resilience while it works toward more consistent profitability.
Return To Positive Net Income
A multi-year return to positive net income suggests BLIS has moved beyond its earlier loss-making phase and established a foundation for financial sustainability. Although earnings remain modest, recurring profitability can support reinvestment and improve the company’s ability to fund growth internally.
Bears Say
Sharp Margin Compression
The substantial decline in gross margin shows that recent revenue growth has not translated efficiently into operating earnings. With EBIT margin still near 4%, changes in product mix, pricing, or costs could materially affect profits and make the recovery in earnings less durable.
Negative Latest Cash Generation
The reversal to negative operating and free cash flow indicates that reported profitability is currently not being converted into cash at the prior rate. Continued cash investment or working-capital pressure could require greater use of the balance sheet and constrain the pace of future expansion.
Modest Profitability Returns
Moderate returns on equity indicate that BLIS is generating profits but has not yet achieved strong capital efficiency. This limits the immediate earnings power of its growing equity base and suggests that further revenue quality, margin recovery, and operating discipline are needed to create stronger shareholder returns.
BLIS Technologies Limited News
BLT FAQ
What was BLIS Technologies Limited’s price range in the past 12 months?
What is BLIS Technologies Limited’s market cap?
When is BLIS Technologies Limited’s upcoming earnings report date?
How were BLIS Technologies Limited’s earnings last quarter?
Is BLIS Technologies Limited overvalued?
Does BLIS Technologies Limited pay dividends?
What is BLIS Technologies Limited’s EPS estimate?
How many shares outstanding does BLIS Technologies Limited have?
What happened to BLIS Technologies Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BLIS Technologies Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BLIS Technologies Limited
BLIS Technologies Limited, together with its subsidiaries, specializes in creating and distributing health-focused products. These offerings are underpinned by unique bacterial strains that exhibit bacteriocin activity. The company prominently features several key probiotic strains: BLIS K12, a supplement engineered to bolster ear, nose, and throat well-being in young children, in addition to enhancing immune function and combating halitosis; BLIS M18, an oral probiotic designed to promote robust dental and gum health; and BLIS Q24, a probiotic formulation aimed at harmonizing and rejuvenating the skin's microbiome, thereby fostering healthier, clearer, and more radiant skin. Established in 2000, BLIS Technologies is based in Dunedin, New Zealand, and maintains a global presence with operations spanning New Zealand, the Asia Pacific region, Europe, the Middle East, Africa, and North America.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Scott Ogilvie Johnson
- Employees
- 43
- Website
- www.blis.co.nz
- Address
- 442 Moray Place, Dunedin, OTA, 9016, NZ
BLIS Technologies Limited (BLT) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 2 | 13 |
| Technical Analysis | 7 | 1 | 2 |
| Moving Averages | 0 | 1 | 11 |




